Healios KK: Change Report (Stock Certificates Eligible for Special Provisions, etc.)
Healios KK: Decision to Apply for Conditional and Time-Limited Approval for ARDS in Japan and ARDS Development Strategy Update
Healios KK: Determination and development strategy for implementing conditions and time-limited approval applications for ARDS therapeutics in Japan
Healios KK: Rescheduling of Conclusion of Development and Commercialization Agreement of MultiStem for ARDS in Japan with Nobelpharma
Healios KK: Notice of further extension of the planned date for concluding a development and sales partnership agreement with Nobel Pharma - Development and sales partnership for ARDS therapeutics in Japan
Healios KK: Change Report (Stock Certificates Eligible for Special Provisions, etc.)
Healios KK: Agreement with the FDA on Pivotal, Global Phase 3 “REVIVE-ARDS” Clinical Trial
Healios KK: Agreement with the US FDA regarding ARDS global phase 3 trial design
Healios KK: Mass holding report (stock certificates subject to special cases, etc.)
Healios KK: Announcement of eNK cell research results at the 5th Annual Meeting of the Japanese Society of Asbestos and Mesothelioma
Healios KK: Share Transfer Report Relating to Third-Party Allocation (New Shares)
Healios KK: Report of transfer of new shares for third-party allotment.
Healios KK: Announcements of individual stocks regarding the presentation of research results on eNK cells at the 83rd Japanese Cancer Association annual meeting.
Healios KK: Confirmatory letter.
Healios KK: Interim report
Healios KK: Semi-annual Report - 14th Period (01/01/2024 - 12/31/2024)
Healios KK: Announcements of individual stocks regarding the recording of financial income and financial expenses.
Healios KK: 2Q FY2024 Financial Results Announcement [IFRS] (Consolidated)
Healios KK: Financial results for the second quarter of 2024.
Healios KK: 2Q financial results presentation material for the December 2024 period
No Data
No Data